In recent decades, significant advances have led to a complete reformulation of clinical and epidemiological concepts about cardiac transthyretin (ATTR) amyloidosis, summarized in .
[…]
Advances in the Diagnosis and Treatment of Cardiac Amyloidosis
SimõesMV, ÁvilaDX, GaribaldiPMM, MesquitaET. Advances in the Diagnosis and Treatment of Cardiac Amyloidosis. ABC Heart Fail Cardiomyop 2023;3(1):e20230024.
Simões,Marcus Vinicius; Ávila,Diane Xavier de; Garibaldi,Pedro Manoel Marques; Mesquita,Evandro Tinoco. Advances in the Diagnosis and Treatment of Cardiac Amyloidosis. ABC Heart Fail Cardiomyop, v. 3, n. 1, e20230024, Aug. 2023.
Simões,M.V., Ávila,D.X. , Garibaldi,P.M.M., & Mesquita,E.T. (2023). Advances in the Diagnosis and Treatment of Cardiac Amyloidosis. ABC Heart Fail Cardiomyop,3(1), e20230024.
Simões,Marcus Vinicius and Ávila,Diane Xavier de and Garibaldi,Pedro Manoel Marques and Mesquita,Evandro Tinoco. Advances in the Diagnosis and Treatment of Cardiac Amyloidosis. ABC Heart Fail Cardiomyop [online]. 2023, vol. 3, n. 1, [cited 2025-09-09], e20230024. Available from: <https://www.abcheartfailure.org/article/advances-in-the-diagnosis-and-treatment-of-cardiac-amyloidosis/>. ISSN .
Figure 1
– Summary of the reformulation of concepts on cardiac amyloidosis. HFpEF: heart failure with preserved ejection fraction.